In keeping with the ongoing Congressional attention on everything related to pharmaceuticals, another bill aimed at improving the integrity of the 340B program – Stretching Entity Resources for Vulnerable (SERV) Communities Act or H.R. 6071 – was recently introduced in the House. In her press release, Representative Matsui (D-CA), the bill’s primary sponsor, stated the […]
The Senate Health, Education, Labor and Pensions (HELP) Committee recently held a hearing entitled, “Examining Oversight Reports on the 340B Drug Pricing Program” to coincide with the release of findings from the U.S. Government Accountability Office (GAO) regarding their efforts to improve oversight for the program. Most of the witness testimony focused on the lack […]
Rep. Carter (R-GA-1) introduced the 340B Optimization Act on April 24, 2018 to increase transparency and ultimately improve care for low income patients. What does the 340B Optimization Act require? The 340B Optimization Act would require certain disproportionate share hospital (DSH) covered entities to annually report on their low-income utilization rate of outpatient hospital services […]
Along with following the Congressional and regulatory activity on the 340B drug pricing program, it is also important to keep abreast of recent analyses of the program in the peer-reviewed literature. The New England Journal of Medicine article, “Consequences of the 340B Drug Pricing Discount Program” examines concerns about the 340B discount program, specifically those […]
Read our latest specialty pharmacy insight report here.